News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Mar 1, 2018
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...
-
Feb 27, 2018
- Janssen supply agreement for ZEJULA® (niraparib) facilitates novel PARPi combination trial with SRA737 in prostate cancer - - SRA737 clinical development program significantly expanded - -...
-
Feb 27, 2018
- Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications – - Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -...
-
Feb 27, 2018
- Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 - VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...
-
Feb 21, 2018
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...